Drug affinity complex raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
studied the effects of CREB and dynorphin on learned helplessness (an animal model for depression) in mice. Overexpression of dominant negative CREB (mCREB) in transgenic mice had an antidepressant effect (in terms of behavior), whereas overexpressing wild-type CREB caused an increase in depression-like symptoms. As described previously, CREB increases transcription of prodynorphin, which gives rise to different dynorphin subtypes. Newton et al. supported this mechanism, as the mCREB was colocalized with decreased expression of prodynorphin. Also, direct antagonism of dynorphin caused antidepressant-like effects similar to those seen with mCREB expression. Thus, the CREB-dynorphin pathway regulates mood as well as cocaine rewards. Shirayama et al. used several animal depression models in rats to describe the effects of dynorphins A and B in depression. The authors found that learned helplessness increases the levels of dynorphins A and B in the hippocampus and nucleus accumbens and that injecting KOR antagonist nor-BNI induces recovery from learned helplessness. Immobilization stress causes increases in the levels of both dynorphins A and B in the hippocampus and nucleus accumbens. Forced swim stress increases the levels of dynorphin A in the hippocampus. Shirayama et al. concluded that both dynorphins A and B were important in stress response. The authors proposed several mechanisms to account for the effects of the KOR antagonist norBNI on learned helplessness.
=== Pharmacokinetics === The metabolism and metabolites of SDA have been studied. It showed more rapid clearance than MDA in rodents and hence may have a shorter elimination half-life and/or duration.
== Nutritional sources == Myo-inositol is naturally present in a variety of foods, although tables of food composition do not always distinguish between lecithin, the relatively bioavailable lipid form and the biounavailable phytate/phosphate form. Foods containing the highest concentrations of myo-inositol and its compounds include fruits, beans, grains, and nuts. Fruits in particular, especially oranges and cantaloupe, contain the highest amounts of myo-inositol. It is also present in beans, nuts, and grains, however, these contain large amounts of myo-inositol in the phytate form, which is not bioavailable without transformation by phytase enzymes. Bacillus subtilis, the microorganism which produces the fermented food natto, produces phytase enzymes that may convert phytic acid to a more bioavailable form of inositol polyphosphate in the gut. Additionally, Bacteroides species in the gut secrete vesicles containing an active enzyme which converts the phytate molecule into bioavailable phosphorus and inositol polyphosphate, which is an important signaling molecule in the human body. Myo-inositol can also be found as an ingredient in energy drinks, either in conjunction with or as a substitute for glucose. In humans, myo-inositol is naturally made from glucose-6-phosphate through enzymatic dephosphorylation.
=== Biosynthesis === In plants cellulose is synthesized at the plasma membrane by rosette terminal complexes (RTCs). The RTCs are hexameric protein structures, approximately 25 nm in diameter, that contain the cellulose synthase enzymes that synthesize the individual cellulose chains. Each RTC floats in the cell's plasma membrane and "spins" a microfibril into the cell wall. RTCs contain at least three different cellulose synthases, encoded by CesA (Ces is short for "cellulose synthase") genes, in an unknown stoichiometry. Separate sets of CesA genes are involved in primary and secondary cell wall biosynthesis. There are known to be about seven subfamilies in the plant CesA superfamily, some of which include the more cryptic, tentatively-named Csl (cellulose synthase-like) enzymes. These cellulose syntheses use UDP-glucose to form the β(1→4)-linked cellulose. Bacterial cellulose is produced using the same family of proteins, although the gene is called BcsA for "bacterial cellulose synthase" or CelA for "cellulose" in many instances. In fact, plants acquired CesA from the endosymbiosis event that produced the chloroplast. All cellulose synthases known belongs to glycosyltransferase family 2 (GT2). Cellulose synthesis requires chain initiation and elongation, and the two processes are separate. Cellulose synthase (CesA) initiates cellulose polymerization using a steroid primer, sitosterol-beta-glucoside, and UDP-glucose. It then utilises UDP-D-glucose precursors to elongate the growing cellulose chain. A cellulase may function to cleave the primer from the mature chain.
=== Further reading === Resnick D, Niwayama G (January 1983). "Entheses and enthesopathy. Anatomical, pathological, and radiological correlation". Radiology. 146 (1): 1–9. doi:10.1148/radiology.146.1.6849029. PMID 6849029.
Sources: en.wikipedia.org
Likewise, the saturated zone of a soil frequently has a higher radon content than the unsaturated zone because of diffusional losses to the atmosphere. In 1971, Apollo 15 passed 110 km (68 mi) above the Aristarchus plateau on the Moon, and detected a significant rise in alpha particles thought to be caused by the decay of 222Rn. The presence of 222Rn has been inferred later from data obtained from the Lunar Prospector alpha particle spectrometer. Radon is found in some petroleum. Because radon has a similar pressure and temperature curve to propane, and oil refineries separate petrochemicals based on their boiling points, the piping carrying freshly separated propane in oil refineries can become contaminated because of decaying radon and its products. Residues from the petroleum and natural gas industry often contain radium and its daughters. The sulfate scale from an oil well can be radium rich, while the water, oil, and gas from a well often contains radon. Radon decays to form solid radioisotopes that form coatings on the inside of pipework.
Irène Joliot-Curie (Physics, 1935) Julian Schwinger (Physics, 1965) Pyotr Kapitsa (Physics, 1978) Frank Wilczek (Physics, 2004) Michael Kremer (Economics, 2009) Jack Szostak (Physiology or Medicine, 2009) Robert Lefkowitz (Chemistry, 2012) Victor Ambros (Physiology or Medicine, 2024, obtained Polish citizenship in 2026) John Hopfield (Physics, 2024)
== Bibliography == Antoni Czubiński, Powstanie Wielkopolskie 1918–1919. Geneza-charakter-znaczenie, Poznań 1978 Antoni Czubiński, Rola Powstania Wielkopolskiego w walce narodu polskiego o powstrzymanie niemieckiego >parcia na wschód<, Przegląd Zachodni 1968, nr 5–6 A. Czubiński, Z.Grot, B.Miśkiiewcz, Powstanie Wielkopolskie 1918–1919. Zarys dziejów, Warszawa 1978 K. Dembski, Wielkopolska w początkach II Rzeczypospolitej. Zagadnienia prawno-ustrojowe, Poznań 1972 Roman Dmowski, Polityka polska i odbudowanie państwa 1925 Z. Grot (ed.), Powstanie wielkopolskie 1918–1919, Poznań 1968 Z. Grot, I. Pawłowski, M. Pirko, Wielkopolska w walce o niepodległość 1918–1919. Wojskowe i polityczne aspekty Powstania Wielkopolskiego, Warszawa 1968 P. Hauser, Niemcy wobec sprawy polskiej X 1918–VI 1919, Poznań 1984 K. Kandziora, Działalność POW w Poznaniu. Przyczynek do historii Polskiej Organizacji Wojskowej zaboru pruskiego w latach 1918–1919, Warszawa 1939 S. Kubiak, Niemcy a Wielkopolska 1918–1919, Poznań 1969 Joseph Lamia: Der Aufstand in Posen (The Uprising in Poznan). Berlin 1919 (in German). Materiały Sesji Naukowej z okazji 50-lecia Powstania Wielkopolskiego 1918/1919, Zaszyty Naukowe UAM 1970, Historia t.10 Witold Mazurczak, Anglicy i wybuch powstania wielkopolskiego. Z dziejów genezy brytyjskiej misji płka H.H.Wade'a w Polsce, [in:] Antoni Czubiński (ed.), Polacy i Niemcy. Dziesięć wieków sąsiedztwa, PWN, Warszawa 1987 Janusz Pajewski, Rodział XXII.
Safrole is listed as a Table I precursor under the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Due to their role in the manufacture of MDMA, safrole, isosafrole, and piperonal are Category I precursors under regulation no. 273/2004 of the European Community. In the United States, safrole is currently a List I chemical. The root bark of American sassafras contains a low percentage of steam-volatile oil, which is typically 75% safrole. Attempts to refine safrole from sassafras bark in mass quantities are generally not economically viable due to low yield and high effort. However, smaller quantities can be extracted quite easily via steam distillation (about 10% of dry sassafras root bark by mass, or about 2% of fresh bark). Demand for safrole is causing rapid and illicit harvesting of the Cinnamomum parthenoxylon tree in Southeast Asia, in particular the Cardamom Mountains in Cambodia. However, it is not clear what proportion of illicitly harvested safrole is going toward MDMA production, as over 90% of the global safrole supply (about 2,000 tonnes or 2,200 short tons per year) is used to manufacture pesticides, fragrances, and other chemicals. Sustainable harvesting of safrole is possible from leaves and stems of certain plants, including the roots of camphor seedlings.
Ticket prices for the 2026 FIFA World Cup initially ranged from $60 for group stage matches to $6,730 for the final—an increase from the USD equivalent of $69 to $1,607 for the 2022 World Cup. However, in September 2025, FIFA confirmed it would use dynamic pricing for tickets for the first time, following the practice used in the 2025 FIFA Club World Cup. Special "hospitality" seats were made available in April 2025. An initial draw period for non-hospitality seats occurred between September 10–19, 2025, limited to Visa cardholders. A second phase ran from October 27–31, 2025, and a third phase started after the final draw of teams on December 5. Sales were capped at four tickets per person per match, and no person was able to purchase more than 40 tickets for the overall tournament. FIFA's official resale platform went live on October 2, 2025. A final "last-minute" sales phase reopened on April 22, 2026, approximately 50 days before the start of the tournament, with tickets for all 104 matches made available on a first-come, first-served basis. By that stage, more than five million tickets had been sold from an expected total exceeding six million, with additional tickets scheduled to be released in phases up to the final, subject to availability. Every city hosting the World Cup in the United States passed a law stating that ticket sales to World Cup events were exempt from state and local sales taxes.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.